Kyowa accelerates US drug development
Japan's Kyowa Hakko Kogyo is accelerating the clinical development of its antibody drugs in the USA. BIW-8405, an interleukin-5 receptor alpha antagonist for the treatment of asthma, which is being developed by BioWa, Kyowa's US drug development unit, has entered Phase Ib trials.
The agent utilizes the company's proprietary potelligent technology, which enhances antibody activity and Kyowa expects peak global sales to reach as much as $5.0 billion. "Since BioWa made a success to file an Investigational New Drug application with the [US Food and Drug Administration] in 18 months, we wish to make this case our model of early drug development in the USA from now on," said Yuzuru Matsuda, president of Kyowa Hakko.
In addition to BIW-8405, BioWa has three antibody drugs utilizing potelligent and one antibody drug for the treatment of cancer. KW-0761, a CC chemokine receptor-4 anti-allergy agent, is now in Phase II in Europe. The compound will shortly enter Phase I Japanese trials in lymphoma.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze